Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden

Background: Societal decision makers increasingly emphasise their need for evidence based economic analyses to make reimbursement decisions. Objective: To analyse the cost utility of adalimumab, on both incremental cost and incremental quality adjusted life years (QALYs), versus traditional disease...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Main Authors: Bansback, N, Brennan, A, Ghatnekar, O
Format: Artigo
Sprog:Inglês
Udgivet: 2005
Fag:
Extended Report
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC1755554/
https://ncbi.nlm.nih.gov/pubmed/15550533
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ard.2004.027565
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker